secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001104659-23-114274
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx reports 96% clinical cure rate in Phase 2 trial of ibezapolstat for C. difficile infection
--------------------------------------------------------------------------------

- 96% clinical cure rate (25/26 patients) in combined Phase 2a and 2b trials of ibezapolstat.
- Ibezapolstat well tolerated; no drug-related serious adverse events; three mild GI events resolved.
- Phase 2b vancomycin-controlled segment terminated early based on high observed cure rate.
- Company plans End-of-Phase 2 FDA meeting in Q1 2024 and advancement to Phase 3.
- Additional analyses of sustained cure, microbiome, and bile acids are forthcoming.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923114274/0001104659-23-114274-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923114274/tm2329812d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-114274

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer